ClinicalTrials.gg
Not yet recruitingNCT07859956LEVO-CSUpdated Oct 6, 2026

Pain After Scheduled Cesarean Delivery: Spinal Morphine With or Without Levobupivacaine Wound Infiltration

An observational study in Pain Management, C Section and Obstetric Pain, sponsored by Fundación Santa Fe de Bogota. Not yet recruiting at 1 site in Colombia. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Fundación Santa Fe de Bogota · Observational

How we know

Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
336
Ages
18 Years and older
Sex
Female
01

Study summary

The goal of this observational study is to learn whether injecting a numbing medicine (levobupivacaine, a local anesthetic) into the surgical wound at the end of a cesarean delivery improves pain control in women who also receive spinal morphine. Spinal morphine is the standard pain treatment for cesarean delivery.

The main questions it aims to answer are:

Do women who receive wound infiltration with levobupivacaine report less pain at 24 hours, 48 hours, and 7 days after surgery than women who do not? Do they have a better quality of recovery, measured with the ObsQoR-10 questionnaire? Do they walk for the first time sooner, and do they need less additional ("rescue") pain medicine in the first 24 hours?

Researchers will compare two groups of women having a scheduled cesarean delivery under spinal anesthesia at Fundación Santa Fe de Bogotá (Bogotá, Colombia). In the first group, the surgeon routinely infiltrates the wound with levobupivacaine when closing. In the second group, the surgeon does not. The study team does not decide which women receive the medicine; this depends only on each surgeon's usual practice. All participants receive the same standard hospital pain treatment: spinal morphine, acetaminophen, and anti-inflammatory medicines.

Participants will:

Receive their usual cesarean care, with no extra procedures because of the study.

Answer short online questionnaires sent by WhatsApp or email at 24 hours, 48 hours, and 7 days after surgery. They will rate their pain on a 0-10 scale at each time point and their recovery with the ObsQoR-10 questionnaire at 24 hours.

Receive a phone call on day 7 reminding them to complete the last questionnaire.

Allow the research team to collect information from their medical record, such as the time to first walk and the use of rescue pain medicine.

The study plans to include 336 women over about 10 months.

Read the detailed description

Background and rationale Intrathecal morphine is the gold standard for analgesia after cesarean delivery. However, 25-80% of women still report moderate to severe pain during the first 24-48 hours. Poorly controlled pain may delay mobilization, increase systemic opioid use, interfere with breastfeeding and newborn care, and has been associated with chronic pain and postpartum depression. International recommendations (PROSPECT, ERAS) support multimodal analgesia. Local anesthetic wound infiltration is simple, inexpensive and reproducible, but evidence on its added benefit over intrathecal morphine is limited and heterogeneous in dose, technique and anatomical plane. Levobupivacaine, the pure S-enantiomer of bupivacaine, has lower cardiovascular and central nervous system toxicity.

Design This is a prospective, single-center, analytical observational cohort study at Fundación Santa Fe de Bogotá, a high-complexity teaching hospital in Bogotá, Colombia, with about 2,000 births per year. Patients are enrolled consecutively over 10 months. Exposure is determined only by the usual clinical practice of each attending obstetrician. The investigators do not assign, randomize or suggest the exposure.

Exposure Exposed cohort: subcutaneous and subfascial infiltration with levobupivacaine 0.75%, 75 mg (one 10 mL ampoule diluted in 10 mL of saline), after closure of the aponeurosis. The drug is Bupinest®, INVIMA registration 2016 M-013339-R2. The total local anesthetic dose, including the spinal dose, stays within the maximum of 2 mg/kg.

Unexposed cohort: no wound infiltration.

Standard institutional analgesia (both cohorts) Spinal anesthesia with intrathecal morphine 100 mcg and fentanyl 25 mcg. Ketorolac 30 mg IV after delivery of the newborn. Acetaminophen 1 g IV at the end of surgery. During the 48-hour hospital stay: oral celecoxib every 12 hours (unless contraindicated), oral acetaminophen 1 g every 8 hours, and IV hyoscine butylbromide 20 mg every 8 hours.

Rescue systemic opioid for pain score >7 or at the patient's request.

Blinding and data collection Outcome assessment and statistical analysis are blinded to exposure. Patient-reported outcomes (pain scale and the validated Spanish version of the ObsQoR-10) are self-administered through automated REDCap surveys sent by WhatsApp or email, which reduces inter-observer variability. Clinical and surgical data are taken from the electronic medical record.

Sample size Sample size was calculated with Epidat 4.2 for comparison of two independent means, using 24-hour pain scores from published data. The parameters were 95% confidence, 80% power and a 1:1 ratio. The result is 336 participants (168 per cohort).

Statistical analysis Pain trajectory (24 h, 48 h, 7 days): linear mixed model for repeated measures. Fixed effects are exposure, time and the exposure × time interaction; the patient is a random effect. Mean between-group differences at each time point are reported with 95% CIs. If model assumptions are not met, robust or ordinal models will be used.

Secondary outcomes:

Time to first ambulation: t-test or Mann-Whitney, and Kaplan-Meier with log-rank if exact times are available.

Rescue analgesia: chi-square or Fisher's exact test, and logistic regression. ObsQoR-10: as a continuous score, and dichotomized at ≥70 points as good recovery.

Adjusted models: multivariable models adjust for confounders, including maternal age, BMI and previous cesarean delivery.

Exploratory subgroups: age, parity, BMI category and previous cesarean delivery.

Significance is set at p \<0.05. The analysis will be done in Rstudio.

Ethics The study is classified as minimal risk under Colombian Resolution 8430 of 1993. It has been approved by the Corporate Research Ethics Committee (CCEI) of Fundación Santa Fe de Bogotá. As an observational Phase IV study of a marketed medicine, it will be notified to INVIMA, the Colombian National Food and Drug Surveillance Institute, before enrollment begins. All participants give electronic informed consent through REDCap. Results will be published regardless of direction.

02

Conditions studied

  • Pain Management
  • C Section
  • Obstetric Pain
  • Levobupivacaine

Keywords

  • Cesarean Section
  • Pain, Postoperative
  • Levobupivacaine
  • Analgesia, Obstetrical
  • Pain Management
03

In context

Labor Pain

426 studies on the registry are indexed under Labor Pain; 76 are open to participants now.

This study's planned enrollment of 336 is above the median of 140 across 63 observational studies indexed under Labor Pain.

Browse Labor Pain studies →

Lead sponsor

Fundación Santa Fe de Bogota is the lead sponsor of 27 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women admitted for cesarean delivery to the Obstetrics Service of Fundación Santa Fe de Bogotá, a private, high-complexity university hospital in Bogotá, Colombia, which attends approximately 2,000 births per year.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women aged 18 years or older
  • Scheduled (elective) cesarean delivery, without prior onset of labor
  • Cesarean delivery performed under spinal anesthesia with intrathecal morphine
  • Single or multiple pregnancy
  • First or subsequent birth (nulliparous or multiparous)
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Exteriorization of the uterus as part of the surgical technique used by the obstetrician
  • Severe bleeding during surgery (obstetric hemorrhage) requiring management beyond medications, such as an intrauterine balloon (Bakri balloon), hemostatic sutures (e.g., B-Lynch) or hysterectomy
  • Known allergy or to bupivacaine, levobupivacaine or other amide-type local anesthetics
  • Known allergy or hypersensitivity to opioids
  • Myasthenia gravis
  • Epilepsy
  • Cardiac arrhythmias
  • Shock
  • Liver damage (hepatic impairment)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
336 participants (estimated)
Patient registry
No

Groups and cohorts

  • Levobupivacaine wound infiltration

    Women undergoing scheduled cesarean delivery under spinal anesthesia with intrathecal morphine and fentanyl whose attending obstetrician, as part of usual clinical practice, performs subcutaneous and subfascial wound infiltration with levobupivacaine 0.75% (75 mg, one 10 mL ampoule diluted in 10 mL of saline) after closure of the aponeurosis. Participants also receive standard institutional multimodal analgesia: ketorolac, acetaminophen, celecoxib and hyoscine butylbromide, with systemic opioid rescue as needed. Exposure is not assigned by the investigators.

    Drug: Levobupivacaine · Drug: Intrathecal Morphine

  • No wound infiltration

    Women undergoing scheduled cesarean delivery under spinal anesthesia with intrathecal morphine and fentanyl whose attending obstetrician, as part of usual clinical practice, does not perform wound infiltration with local anesthetic. Participants receive the same standard institutional multimodal analgesia: ketorolac, acetaminophen, celecoxib and hyoscine butylbromide, with systemic opioid rescue as needed. Exposure is not assigned by the investigators.

    Drug: Intrathecal Morphine

Interventions

  • Subcutaneous and subfascial wound infiltration with levobupivacaine 0.75%, 75 mg (one 10 mL ampoule diluted in 10 mL of saline, total 20 mL), performed after closure of the aponeurosis at the end of cesarean delivery, as part of the attending obstetrician's usual practice. Given in addition to the same standard institutional multimodal analgesia received by all participants: intrathecal morphine plus fentanyl, ketorolac, acetaminophen, celecoxib and hyoscine butylbromide, with systemic opioid rescue as needed. Not assigned by the investigators.

    Also known as: Bupinest®, Levobupivacaine hydrochloride

  • DrugMorphineStudies of MorphineMorphine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Single-dose intrathecal morphine plus fentanyl given with spinal anesthesia for cesarean delivery, as part of the standard institutional multimodal analgesia protocol (with ketorolac, acetaminophen, celecoxib and hyoscine butylbromide; systemic opioid rescue as needed).

    Also known as: Spinal morphine

06

What researchers measure

Primary outcomes

  1. Postoperative pain intensity (Visual Analog Scale)

    Patient-reported pain intensity on a 0 to 10 Visual Analog Scale (0 = no pain, 10 = worst imaginable pain); higher scores indicate worse pain. Self-administered through automated REDCap surveys sent by WhatsApp or email, with outcome assessors and the statistician blinded to exposure. Pain trajectories will be compared between cohorts using a linear mixed model for repeated measures (fixed effects: cohort, time and cohort-by-time interaction; patient as random effect), reporting mean between-group differences with 95% confidence intervals at each time point.

    Time frame: 24 hours, 48 hours and 7 days after cesarean delivery

Secondary outcomes

  1. Quality of obstetric recovery (ObsQoR-10 score)

    Patient-reported quality of recovery measured with the validated Spanish version of the Obstetric Quality of Recovery-10 questionnaire (ObsQoR-10-Spanish). It includes 10 items scored 0 to 10, for a total score of 0 to 100; higher scores indicate better recovery. Self-administered through an automated REDCap survey. Compared between cohorts as a continuous variable.

    Time frame: 24 hours after cesarean delivery

  2. Proportion of participants with good obstetric recovery (ObsQoR-10 score ≥70)

    Percentage of participants classified as having good recovery (ObsQoR-10 total score ≥70 points) versus poor recovery (\<70 points), using the cut-off reported in the literature. Compared between cohorts with risk ratios or odds ratios and 95% confidence intervals.

    Time frame: 24 hours after cesarean delivery

  3. Time to first ambulation

    Time in hours from the end of cesarean delivery until the participant walks for the first time, obtained from the medical record. Compared between cohorts as a continuous variable, and with time-to-event analysis (Kaplan-Meier, log-rank test) if exact times are available.

    Time frame: From end of surgery up to 24 hours after cesarean delivery

  4. Use of rescue analgesia

    Percentage of participants who require rescue systemic opioid analgesia in addition to the standard institutional regimen (given for a pain score \>7 or at the patient's request), obtained from the medical record. Compared between cohorts with risk ratios or odds ratios and 95% confidence intervals, adjusted with multivariable logistic regression.

    Time frame: First 24 hours after cesarean delivery

07

Study locations

1 site
08

References and documents

Publications

  • Garmi G, et al. Efficacy of single wound infiltration with bupivacaine and adrenaline during cesarean delivery for reduction of postoperative pain: a randomized clinical trial. JAMA Netw Open. 2022;5(11):e2242203. doi:10.1001/jamanetworkopen.2022.42203 Roofthooft E, et al. PROSPECT guideline for elective caesarean section: updated systematic review and procedure-specific postoperative pain management recommendations. Anaesthesia. 2021;76(5):665-680. doi:10.1111/anae.15339 Sultan P, Monks DT, Sharawi N, et al. Guidelines for postoperative care in cesarean delivery: Enhanced Recovery After Surgery Society recommendations (part 3). Am J Obstet Gynecol. doi:10.1016/j.ajog.2025.01.038 Sultan P, et al. Evaluation of inpatient postpartum recovery using the Obstetric Quality of Recovery-10 patient-reported outcome measure: a single-center observational study. Am J Obstet Gynecol MFM. 2020;2(4):100202. doi:10.1016/j.ajogmf.2020.100202 Guevara J, et al. Development and validation of a Spanish version of the Obstetric Quality of Recovery-10 item score (ObsQoR-10-Spanish). BJA Open. 2024;10:100269. doi:10.1016/j.bjao.2024.100269 Niklasson B, et al. Intraoperative injection of bupivacaine-adrenaline close to the fascia reduces morphine requirements after cesarean section: a randomized controlled trial. Acta Obstet Gynecol Scand. 2012;91(12):1433-1439. doi:10.1111/j.1600-0412.2012.01480.x

Individual participant data

Plan to share: No — Individual participant data will not be shared outside the research team, as the informed consent approved by the institutional ethics committee does not include authorization for data sharing with external researchers. Data will be stored confidentially in the institutional REDCap platform of Fundación Santa Fe de Bogotá for at least 5 years. Aggregated results will be published regardless of direction.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jul 2027, 9 months later.

Of 31 non-industry observational studies under Labor Pain, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 32. This study's planned 9 months is close to that.

Counting every sponsor, half of 32 studies reached it within 9 months; a quarter within 6 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 6, 2026
StartEst.
Oct 14, 2026
Primary completionEst.
Jul 14, 2027
CompletionEst.
Sep 14, 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07859956
Lead sponsor
Fundación Santa Fe de Bogota
Responsible party
Camilo Hernandez de Alba (Gynecologist, obstetrician, specialist in maternal-fetal medicine and fetal surgery, Fundación Santa Fe de Bogota) — Principal investigator
First posted
Oct 6, 2026
Start date
Oct 14, 2026 (estimated)
Primary completion
Jul 14, 2027 (estimated)
Completion
Sep 14, 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Karen D Cepeda, MD
Contact
investigador.gorh@fsfb.org.co
+573173691828
Camilo Hernandez, MD
Contact
chernandezdea@hotmail.com
+573153891355

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion